Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults

Koychev,I.,Adler,A. I.,Edison,P.,Tom,B.,Milton,J. E.,Butchart,J.,Hampshire,A.,Marshall,C.,Coulthard,E.,Zetterberg,H.,Hellyer,P.,Cormack,F.,Underwood,B. R.,Mummery,C. J.,Holman,R. R.

DOI: https://doi.org/10.1136/bmjopen-2023-081401

IF: 3.006

2024-06-22

BMJ Open

Abstract:Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), currently marketed for type 2 diabetes and obesity, may offer novel mechanisms to delay or prevent neurotoxicity associated with Alzheimer's disease (AD). The impact of semaglutide in amyloid positivity (ISAP) trial is investigating whether the GLP-1 RA semaglutide reduces accumulation in the brain of cortical tau protein and neuroinflammation in individuals with preclinical/prodromal AD. Methods and analysis ISAP is an investigator-led, randomised, double-blind, superiority trial of oral semaglutide compared with placebo. Up to 88 individuals aged ≥55 years with brain amyloid positivity as assessed by positron emission tomography (PET) or cerebrospinal fluid, and no or mild cognitive impairment, will be randomised. People with the low-affinity binding variant of the rs6971 allele of the Translocator Protein 18 kDa (TSPO) gene, which can interfere with interpreting TSPO PET scans (a measure of neuroinflammation), will be excluded. At baseline, participants undergo tau, TSPO PET and MRI scanning, and provide data on physical activity and cognition. Eligible individuals are randomised in a 1:1 ratio to once-daily oral semaglutide or placebo, starting at 3 mg and up-titrating to 14 mg over 8 weeks. They will attend safety visits and provide blood samples to measure AD biomarkers at weeks 4, 8, 26 and 39. All cognitive assessments are repeated at week 26. The last study visit will be at week 52, when all baseline measurements will be repeated. The primary end point is the 1-year change in tau PET signal. Ethics and dissemination The study was approved by the West Midlands—Edgbaston Research Ethics Committee (22/WM/0013). The results of the study will be disseminated through scientific presentations and peer-reviewed publications. Trial registration number ISRCTN71283871.

medicine, general & internal

What problem does this paper attempt to address?

This paper describes a randomized double-blind controlled trial called "ISAP" which aims to investigate the effects of oral medication semaglutide (a glucagon-like peptide-1 receptor agonist) on community-dwelling adults in the UK who are amyloid-positive (potentially in early stages of Alzheimer's disease). The study primarily focuses on whether semaglutide can reduce the accumulation of cortical tau protein and neuroinflammation in the brain to slow down or prevent the progression of Alzheimer's disease. The trial aims to recruit 88 participants aged 55 and above who have confirmed amyloid deposits in the brain through positron emission tomography (PET) or cerebrospinal fluid testing, and who have no or only mild cognitive impairment. Participants will be randomly assigned to either the once-daily semaglutide or placebo group, with the dosage gradually increasing from 3 mg to 14 mg. The primary endpoint is the change in tau protein PET signal within 1 year. The research findings will be published through scientific reports and peer-reviewed publications.